UK Markets closed

Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
35.55+0.20 (+0.57%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close35.35
Open35.52
Bid35.49 x 900
Ask35.51 x 1000
Day's range35.27 - 35.63
52-week range33.84 - 44.13
Volume267,294
Avg. volume319,017
Market cap21.105B
Beta (5Y monthly)1.01
PE ratio (TTM)15.43
EPS (TTM)2.30
Earnings dateN/A
Forward dividend & yield0.82 (1.97%)
Ex-dividend date24 May 2021
1y target est40.82
  • Business Wire

    Fresenius Medical Care Partners with JMS Co. Ltd. to Advance Home Dialysis Treatment in Japan

    HONG KONG, September 17, 2021--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has today announced a strategic distribution partnership with JMS Co. Ltd, a provider of medical devices and pharmaceuticals, in Japan. Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care’s innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to suit their lifestyle, e

  • Zacks

    Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y

    Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.

  • EQS Group

    Fresenius Medical Care AG & Co. KGaA reports results in line with expectations for the second quarter and confirms 2021 outlook

    DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Half Year Results30.07.2021 / 07:03 The issuer is solely responsible for the content of this announcement. As assumed, COVID-19 pandemic continued to impact organic growth in dialysis and downstream businesses Patient excess mortality rates significantly reduced Negative exchange rate effects continue Earnings development impacted by phasing and strong prior-year base, as indicated Financial targets for FY 2021 confirmed FME25 progra